Our finding that UA enhanced the antitumor effect of gemcitabine in an animal model by inhibiting NF-κB and its downstream targets—leading to the inhibition of proliferation, angiogenesis, and invasion—suggests that UA has significant potential for the treatment of pancreatic cancer. This evidence concerns the gene NFKB1 and pancreatic neoplasm.